All In Biotech

Drug Trial Radar · NCT00592163

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 2007

Primary completion

Jan 4, 2009

Study completion Jan 4, 2010

Sponsor

Lead sponsor
Alaunos TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Conditions

  • Advanced Solid Tumors
  • Lymphomas

Interventions

  • ZIO-101-C (Darinaparsin)Drug

    Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. toxicitiesTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.